Febuxostat efficacy in allopurinol-resistant tophaceous gout

Journal of Clinical Rheumatology

Volumn 17, Issue 4, 2011, Pages 204-206

  Uh, Mitchell ^a   Reid, Graham ^b  

^a Department of Medicine ^*  (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Allopurinol; Dual energy CT; Febuxostat; Tophaceous gout

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; PROBENECID; URIC ACID;

ADULT; ARTHRALGIA; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GOUT; HUMAN; KNEE PAIN; NAUSEA; PRIORITY JOURNAL; SYMPTOM; TOPHACEOUS GOUT; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL;

ALLOPURINOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; THIAZOLES; TREATMENT FAILURE; TREATMENT OUTCOME; URIC ACID; YOUNG ADULT;

EID: 80051795855     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0b013e31821c0cae     Document Type: Article

References (14)

1. Choi HK, Al-Arfaj AM, Eftekhari A, et al. Dual energy computed tomography in tophaceous gout. Ann Rheum Dis. 2009;68: 1609-1612.
2. Butler JV, Whittington JE, Holland AJ, et al. Prevalence of, and risk factors for, physical ill-health in people with Prader-Willi syndrome: a population-based study. Dev Med Child Neurol. 2002;44:248-255. (Pubitemid 34406514)
3. Asanuma H, Nagatsuma K, Baba S, et al. A case of Prader-Willi syndrome accompanied with a renal stone [Japanese]. Hinyokika Kiyo. 1998;44:37-39. (Pubitemid 128514502)
4. Santos VM, Henrique de Paula F, Osterne EM, et al. Morbid obesity in an adolescent with Prader-Willi syndrome. Rev Med Chil. 2009;137:264-268.
5. Becker MA, Losman MJ, Rosenberg AL, et al. Phosphoribosylpyrophosphate synthetase superactivity. A study of five patients with catalytic defects in the enzyme. Arthritis Rheum. 1986;29:880-888. (Pubitemid 16072887)
6. Jinnah HA, De Gregorio L, Harris JC, et al. The spectrum of inherited mutations causing HPRT deficiency: 75 new cases and a review of 196 previously reported cases. Mutat Res. 2000;463:309-326.
7. Bleyer AJ, Hart TC. Genetic factors associated with gout and hyperuricemia. Adv Chronic Kidney Dis. 2006;13:124-130.
8. Sundy JS, Hershfield MS. Uricase and other novel agents for the management of patients with treatment-failure gout. Curr Rheumatol Rep. 2007;9:258-264. (Pubitemid 46954786)
9. Kelley WN, Rosenbloom FM, Miller J, et al. An enzymatic basis for variation in response to allopurinol. Hypoxanthine-guanine phosphoribosyltransferase deficiency. N Engl J Med. 1968;278:287-293.
10. Simmonds HA, Gibson T, Huston GJ, et al. Gout resistant to allopurinol: poor compliance or non-response. Adv Exp Med Biol. 1984;165(pt A):171-174.
11. Moolenburgh JD, Reinders MK, Jansen TL. Rasburicase treatment in severe tophaceous gout: a novel therapeutic option. Clin Rheumatol. 2006;25:749-752. (Pubitemid 44120930)
12. Massey V, Komai H, Palmer G, et al. On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3, 4-d]pyrimidines. J Biol Chem. 1970;245:2837-2844.
13. Takano Y, Hase-Aoki K, Horiuchi H, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci. 2005;76:1835-1847. (Pubitemid 40215224)
14. Okamoto K, Eger BT, Nishino T, et al. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem. 2003;278:1848-1855. (Pubitemid 36801423)